We screened six ICC cell lines (including two Cluster1A, two Cluster1B and two Cluster2A mutant cell lines) against a panel of compounds which are being tested in clinical trials or FDA-approved, including ones targeting tyrosine kinase receptors, epigenetic regulation, metabolism, DNA damage, and cell cycle (Figure 6A and Table S10). This evidence concerns the gene NTRK1 and intrahepatic cholangiocarcinoma.